HO
Press Releases
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment
